Drugs / AP31969
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07449390 | Apr → May 2026 | — | Acesion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT06066099 | Oct 2023 → Mar 2025 | — | Acesion Pharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07267949 | Oct 2025 → May 2027 expected | atrial fibrillation | Acesion Pharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-15 | Acesion Pharma | Results Acesion Pharma Announces Positive Pre-Clinical Data for AP31969 acesionpharma.com ↗
In two such models, AP31969 has demonstrated a low risk of proarrhythmia with robust differentiation to existing drugs, which have a high risk of proarrhythmia, tested in the same models. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-06 | Acesion Pharma | Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation acesionpharma.com ↗ |
| 2023-05-15 | Acesion Pharma | Acesion Pharma Announces Positive Pre-Clinical Data for AP31969 acesionpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP31969 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07449390 ↗ |
| Route | Oral | “Oral tablets” NCT06066099 ↗ |